The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes.

  title={The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes.},
  author={Asger Lund and Tina Vilsb{\o}ll and Jonatan I Bagger and Jens Juul Holst and Filip Krag Knop},
  journal={American journal of physiology. Endocrinology and metabolism},
  volume={300 6},
  • A. LundT. Vilsbøll F. Knop
  • Published 1 June 2011
  • Medicine, Biology
  • American journal of physiology. Endocrinology and metabolism
Type 2 diabetes mellitus (T2DM) is associated with reduced suppression of glucagon during oral glucose tolerance test (OGTT), whereas isoglycemic intravenous glucose infusion (IIGI) results in normal glucagon suppression in these patients. [] Key Method Glucagon responses were measured during a 3-h 50-g OGTT (day A) and an IIGI (day B) in 10 patients with T2DM [age (mean ± SE), 51 ± 3 yr; body mass index, 33 ± 2 kg/m(2); HbA(1c), 6.5 ± 0.2%].

Figures and Tables from this paper

Role of a Dual Glucose-Dependent Insulinotropic Peptide (GIP)/Glucagon-like Peptide-1 Receptor Agonist (Twincretin) in Glycemic Control: From Pathophysiology to Treatment

The latest evidence showed a synergetic effect when GIP was combined with GLP-1 in monomolecular co-agonists, and compared with the separate infusion of each hormone, the combination increased both insulin response and glucagonostatic response.

The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion—A Review

The mechanisms by which the two incretins modulate alpha cell secretion of glucagon are described, the effects of co-administration of GLP-1 and GIP on glucagon secretion, and the potential role of glucagons in the therapeutic effects observed with novel unimolecular dual GLp-1/GIP receptor agonists are discussed.

Small Intestinal Glucose Delivery Affects the Lowering of Blood Glucose by Acute Vildagliptin in Type 2 Diabetes.

These observations warrant further study to clarify whether type 2 diabetic patients with relatively more rapid gastric emptying have greater glucose lowering during treatment with DPP-4 inhibitors.

The Effect of Exogenous Glucose-Dependent Insulinotropic Polypeptide in Combination With Glucagon-Like Peptide-1 on Glycemia in the Critically Ill

The addition of GIP to GLP-1 does not result in additional glucose-lowering or insulinotropic effects in critically ill patients with acute-onset hyperglycemia, and GIP increased glucagon concentrations slightly before nutrient delivery, but not thereafter.

Nephroprotective Properties of the Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) Receptor Agonists

  • T. Bulum
  • Medicine, Biology
  • 2022
The nephroprotective properties of dual GIP and GLP-1 receptor agonists as a new drug to treat type 2 diabetes are presented and preliminary results suggest that tirzepatide improves kidney outcomes in adults with type 1 diabetes with increased cardiovascular risk.

The incretin hormones, glucose-dependent insulinotropic poly- peptide (GIP) and glucagon-like peptide-1 (GLP-1), are gut hor- mones secreted from enteroendocrine cells in the intestinal mu- cosa. They act as key regulators-in a glucose-dependent fashion-of pancreatic alpha and beta cell secretion in

This thesis is based on three studies aiming to elucidate physiological and pathophysiological aspects of gastrointestinally mediated effects on alpha cell and beta cell secretion and weight regulating properties of GLP-1 and glucagon.

The role of glucagon on type 2 diabetes at a glance

It has been proposed that the glucagonostatic and insulinotropic effects of GLP-1RA equally contribute to their hypoglycemic efficacy.

Postprandial responses of incretin and pancreatic hormones in non-diabetic patients with end-stage renal disease.

Non-diabetic patients with ESRD were characterized by reduced postprandial insulin responses despite increased secretion of the insulinotropic incretin hormone GLP-1, and fasting levels and baseline-corrected responses of glucagon were elevated and gastric emptying was delayed in these patients.

The Gut: A Key to the Pathogenesis of Type 2 Diabetes?

Although disturbances in gastric emptying are not consistent findings in type 2 diabetes, the incretin system is seriously impaired, probably associated with insulin resistance and obesity.



Increased postprandial GIP and glucagon responses, but unaltered GLP-1 response after intervention with steroid hormone, relative physical inactivity, and high-calorie diet in healthy subjects.

The data suggest that increased postprandial GIP and glucagon responses may occur as a consequence of insulin resistance and/or reduced glucose tolerance and that acute disruption of glucose homeostasis does not result in reduced postPRandial GLP-1 responses as observed in some individuals with type 2 diabetes mellitus.

Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?

Factors are identified that may determine individual incretin secretory responses and explain some of the variations in published findings of group differences in GLP-1 responses to nutrient intake that do not support the contention of a generalised defect in nutrient-related GLp-1secretory responses in type 2 diabetes patients.

Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients

Lack of GIP amplification of the late phase insulin response to glucose, which contrasts markedly to the normalising effect of GLP-1, could be a key defect in insulin secretion in Type II diabetic patients.

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.

In mild type-2 diabetes, GLP-1 [7-36 amide], in contrast to GIP, retains much of its insulinotropic activity and lowers glucagon concentrations.

Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans.

GLP-2 reduces gastric acid secretion but does not seem to have an influence on gastric emptying, and changes in postprandial lipid excursions seem to reflect enhanced intestinal nutrient absorption during GLp-2 administration.

In vivo and in vitro degradation of glucagon-like peptide-2 in humans.

GLP-2 is extensively degraded to GLP-3-33 in humans, presumably by DPP-IV, supporting the possibility of sc use in patients with intestinal insufficiency.

Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus

Attenuated and delayed glucagon suppression in patients with type 2 diabetes occurs after oral ingestion of glucose, while isoglycaemic i.v. administration of glucose results in normal suppression of glucagon, and it is suggested that this phenomenon contributes both to the glucose intolerance and to the reduced incretin effect observed in patients.

Separate Impact of Obesity and Glucose Tolerance on the Incretin Effect in Normal Subjects and Type 2 Diabetic Patients

Potentiation of insulin secretion, glucose sensing, glucagon-like peptide-1 release, and glucagon suppression are physiological manifestations of the incretin effect.

Impact of lack of suppression of glucagon on glucose tolerance in humans.

It is indicated that lack of suppression of glucagon can cause substantial hyperglycemia when insulin availability is limited, therefore implying that inhibitors of glucagons secretion and/or glucagon action are likely to be useful therapeutic agents in such individuals.

Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon.

Treatment with GLP-2 improves intestinal absorption and nutritional status in short-bowel patients with impaired postprandial GLp-2 secretion in whom the terminal ileum and the colon have been resected.